SIBN — SI-BONE, Inc.
SIBN dilution and offerings
- Dilution risk: Low
- Active shelf: S-3ASR (Feb 2026)
- Float: 39.5M shares
$20.22-4.76%
Last close: · regular session
After-hours $19.25 -4.80% ·
Last 60 sessions
Dilution risk: low; active automatic shelf (S-3ASR, Feb 2026). Float: 39.5M shares. Latest SEC filing: 4 on Nov 2, 2026. SIBN closed at $20.22 (-4.76%) on Nov 2, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for SIBN in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
- Exchange: NASDAQ
- Employees: 349
- Website: https://si-bone.com
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Latest SEC filings for SIBN
Latest SIBN news
- Si-bone reaffirms 2026 revenue outlook as Onyx launch targets $5B annual market opportunity Read article
- Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates Read article
- SI-BONE GAAP EPS of -$0.08 beats by $0.05, revenue of $55.7M beats by $0.39M Read article
- Is SI-BONE Inc (SIBN) Overvalued After 3.8% Rally? GF Value Says Overvalued Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.